Abbott has introduced Alinity, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.
Diagnostic testing guides 70 percent of health care decisions. Global testing volumes are rising due to an aging population, the growing management of chronic diseases and increased access to care. At the same time, health systems are facing pressures to perform testing as efficiently as possible with limited staff and space while also reducing costs.
Many institutions and labs use multiple diagnostic platforms, often within a larger health care network. As they serve more patients and try to improve service levels with fewer qualified technicians, institutions are looking for new technologies that can help maximize testing efficiencies and help better manage resources.
Designed with universal, intuitive interfaces as well as common software and hardware, Abbott’s Alinity systems will have the ability to work together, providing greater capacity and simplifying the user experience. Several of the platforms will be designed to run more tests in less space, generate test results faster and minimize human errors.
“With our unified family of testing instruments, we’ll be able to offer more efficiency, flexibility and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care,” said Brian Blaser, executive vice president, Diagnostics Products, Abbott.
Abbott expects Alinity launches to begin later this year and continue into 2017.